Pharmaceutical manufacturers are executing unprecedented capital expansion programs to overcome sustained supply shortages of GLP-1 metabolic therapies.
Fill-Finish Capacity Constraints
The primary supply bottleneck rests in specialized injectable delivery systems and sterile fill-finish operations. Contract development and manufacturing organizations (CDMOs) are securing multi-year commitments from drug sponsors to construct dedicated production lines.
Payer Coverage and Economic Exposure
National healthcare systems and private insurers are implementing stringent prior-authorization criteria to manage budget exposure, prompting manufacturers to seek efficiency gains that could lower per-dose production costs.